Ravi A. Madan, M.D.

Dr. Madan is a Senior Clinician at the National Cancer Institute (NCI), conducting clinical research in prostate cancer with a focus on immunotherapy strategies. Dr. Madan received his M.D. from the Rutgers-New Jersey Medical School in 2001 and completed his internal medicine residency at Rutgers-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. In 2009 he was appointed to the position of Assistant Clinical Investigator. In 2014 he was made the Clinical Director of the Genitourinary Malignancies Branch and in 2018 he was appointed to the role of Senior Clinician. He holds a joint appointment in the Center for Immuno-Oncology which forms the basis for many of his clinical collaborations. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.

Dr. Madan serves on many international review and research committees, including for organizations like the Veteran's Association and Prostate Cancer UK. He also currently serves as the Chair of the FDA's Oncologic Drugs Advisor Committee (ODAC).